Biomarkers for synaptic dysfunction in Alzheimer’s disease  

作　　者：Ruiqing Ni 

机构地区：[1]Institute for Regenerative Medicine,University of Zurich,Institute for Biomedical Engineering,ETH Zurich and University of Zurich,Zurich,Switzerland Department of Nuclear Medicine,Inselspital,Bern University Hospital,University of Bern,Bern,Switzerland

出　　处：《Neural Regeneration Research》2026年第2期683-684,共2页中国神经再生研究(英文版)

基　　金：supported by Swiss Center for Applied Human Toxicology(SCAHT AP22-01)(to RN).

摘　　要：Alzheimer’s disease(AD)is the most common cause of dementia,characterized by progressive cognitive decline,and affects over 55 million people worldwide.AD is pathological featured by the aberrant accumulation of amyloid-βplaques,neurofibrillary tangles formed by hyperphosphorylated tau,synaptic loss,and dysfunction of neurotransmitter systems.Evidence from in vivo and autopsy studies has consistently shown that synaptic dysfunction and loss are strongly correlated with cognitive decline in AD,particularly in brain regions such as the hippocampus and cortex,which are critical for memory formation and processing.This perspective highlights recent histopathological findings related to synaptic dysfunction in AD,advancements in the development of imaging and fluid-based biomarkers for synaptic loss,and future studies.

关 键 词：vivo autopsy studies synaptic dysfunction loss alzheimer s disease ad amyloid plaques cognitive declineand Alzheimers disease dysfunction neurotransmitter systemsevidence synaptic dysfunction 

分 类 号：R749.1[医药卫生—神经病学与精神病学]